What is Tempus AI's key focus?

Tempus AI applies artificial intelligence to clinical and molecular data, aiming to personalize treatment, especially in oncology, and extend its technology across a wider range of diseases.

How did Tempus AI's Q3 2025 results perform?

Tempus AI reported a blowout Q3 2025, with its genomics business delivering a standout performance. Oncology test volumes jumped around 27%, while hereditary testing surged, pushing total genomics revenue to approximately $253 million.

What is the market sentiment towards Tempus AI?

Wall Street sentiment towards Tempus AI strengthened on November 5, 2025, following the company's Q3 results, with three major firms reiterating positive ratings and updating their targets.

Home / Business and Economy / Tempus AI Surges on Genomics Boost and AI Deployment

Tempus AI Surges on Genomics Boost and AI Deployment

17 Nov

•

Summary

Tempus AI's Q3 results beat expectations, with genomics revenue up ~27%
AI deployment in clinical practice could drive strong long-term growth
Adjusted EBITDA turned positive, but GAAP net loss due to costs

Tempus AI Surges on Genomics Boost and AI Deployment

On November 5, 2025, Tempus AI, Inc. (NASDAQ:TEM) reported strong Q3 results, sending Wall Street sentiment soaring. The health-tech company, which applies artificial intelligence to clinical and molecular data, saw its genomics business deliver a standout performance.

Tempus' oncology test volumes jumped around 27%, while hereditary testing surged, pushing total genomics revenue to approximately $253 million. This "Ambry-boosted" genomics engine was the key driver behind the company's overall sales of $334 million. The Data/Services segment also grew, with Insights licensing leading the way, allowing Tempus to spread its fixed costs more widely and lift gross profit to around $210 million.

While Tempus' adjusted EBITDA turned positive, its GAAP net income remained in the red due to stock compensation, new Ambry amortization, and a $12 million debt-extinguishment hit. However, the market's reaction was not about demand, as management raised the full-year guidance, citing the durability of these growth levers.